CVS Health (CVS) Rebounds +12% in Last 30 Days: Key Drivers and Performance Insights
Key Takeaways
- CVS Health stock rose approximately +12% over the last 30 days, rebounding from late-March lows around $70 amid positive market sentiment and sector outperformance.
- Over the past quarter, shares gained +12%, supported by a strong Q4 2025 earnings beat despite intra-quarter volatility.
- Key drivers include robust Q4 revenue growth to a record $105.7 billion and adjusted EPS of $1.09, exceeding estimates.
- Broader influences encompass health insurance segment pressures balanced by pharmacy services strength and positive analyst attention.
- Stock exhibited volatile but upward-trending movement, outperforming the medical sector in recent periods.
CVS Health (CVS) Company Overview and Market Position
CVS Health Corporation (CVS) stands as a diversified healthcare company operating one of the largest pharmacy retail chains in the United States, with over 9,000 locations that provide prescription drugs, health products, and MinuteClinic walk-in services. Its business spans three core segments: Health Care Benefits through Aetna for health insurance plans, Pharmacy Services for pharmacy benefit management (PBM) that processes prescriptions for clients, and the Consumer segment covering retail pharmacies and front-store sales. In my view, CVS holds a strong position in both retail pharmacy and PBM spaces, going up against competitors like Walgreens Boots Alliance (WBA) and UnitedHealth Group (UNH). The integrated model—blending retail, PBM, and insurance—offers resilience to challenges like reimbursement pressures, though it also carries regulatory risks in Medicare Advantage plans, which helps explain some of the recent price volatility linked to earnings cost visibility.
CVS Health (CVS) Stock Price Performance: 30 Days vs. Quarter
Over the last 30 days, CVS stock has advanced +12%, moving from around $70 to a recent close near $78. The path has been volatile but clearly upward-trending, with a notable rebound kicking off in early April from $73, hitting highs close to $79, and then settling in the $77-$78 range.
Looking at the past quarter, shares delivered a +12% gain, recovering from mid-January levels near $74. There were early peaks above $83, a mid-quarter pullback to the low $70s, and solid recent strength. The performance stayed range-bound at points but trended higher overall, in line with healthcare market movements.
Key Factors Behind CVS Stock's 30-Day Rise
The +12% gain in the last 30 days reflects renewed investor confidence after a March dip, as CVS outperformed the medical sector's decline. I also checked recent sessions with Tickeron’s AI Trend Prediction Engine, which highlighted consistent gains like a 3.32% intraday move amid broader market advances where CVS often exceeded benchmarks. Analyst coverage has turned more positive, noting the stock's upward momentum—such as a 4.2% climb in early April that beat the sector's 4.81% loss. Resilience in pharmacy and benefits segments, along with stabilizing healthcare demand, drove the rebound. Without major earnings or M&A events, the lift came from sustained operational strength from earlier quarters.
Quarterly Performance Drivers for CVS Stock
The quarter's +12% increase was driven primarily by CVS Health's Q4 2025 earnings on February 10, 2026, where adjusted EPS reached $1.09—beating consensus estimates of $1.00 by 9%—and revenue hit $105.7 billion, topping forecasts by 2% with 8% year-over-year growth. Full-year 2025 revenue also marked a record at $402.1 billion, up 7.8%. These figures demonstrated efficiency in pharmacy services and health benefits, even with Medicare cost pressures. Volatility stemmed from a January drop after guidance review and a March pullback amid valuation worries and sector shifts. Institutional buying and beats against the S&P 500 in key sessions boosted returns. Broader supports included healthcare spending trends and PBM regulatory stability, with CVS's integrated care positioning helping offset headwinds.
Trending AI Robots: A Tool I Use for Smarter Trading
In my analysis and trading routine, I often turn to Tickeron’s Trending AI Robots page, which spotlights the best-performing AI trading bots from a library of hundreds of algorithms trading thousands of tickers across markets. It curates bots excelling lately based on current conditions and strategies like momentum, mean reversion, or pattern recognition for short-term, swing, or long-term plays. Metrics such as win rate, average return, and Sharpe ratio give clear performance views. Whether for scalping or trend following, this resource provides transparent live insights that have helped refine my approach.
CVS Stock Outlook: What to Watch Moving Forward
From what I see, investors should keep an eye on Q1 2026 earnings for insights into Medicare Advantage enrollment, PBM pricing, and Health Care Benefits margins. Watch for retail pharmacy consolidation, telehealth growth, and shifts in competitive landscape. Macro elements like interest rates, inflation on consumer spending, and policy changes in healthcare will matter. Potential upsides lie in cost controls, Aetna membership expansion, and MinuteClinic usage, while risks include PBM regulatory probes or drug pricing reforms—this is something I’m watching closely.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
Contributor
CVS in -2.18% downward trend, sliding for three consecutive days on October 01, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where CVS declined for three days, in 171 of 285 cases, the price declined further within the following month. The odds of a continued downward trend are 60%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CVS as a result. In 51 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 58%.
The Aroon Indicator for CVS entered a downward trend on October 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CVS's RSI Indicator exited the oversold zone, 21 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 70%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 30 of 53 cases where CVS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 57%.
The Moving Average Convergence Divergence (MACD) for CVS just turned positive on October 06, 2026. Looking at past instances where CVS's MACD turned positive, the stock continued to rise in 34 of 51 cases over the following month. The odds of a continued upward trend are 67%.
Following a +2.12% 3-day Advance, the price is estimated to grow further. Considering data from situations where CVS advanced for three days, in 232 of 346 cases, the price rose further within the following month. The odds of a continued upward trend are 67%.
CVS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 2 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: CVS's P/B Ratio (1.410) is slightly lower than the industry average of (3.247). P/E Ratio (23.179) is within average values for comparable stocks, (139.958). CVS's Projected Growth (PEG Ratio) (0.206) is slightly lower than the industry average of (0.786). CVS has a moderately high Dividend Yield (0.030) as compared to the industry average of (0.009). P/S Ratio (0.283) is also within normal values, averaging (0.569).
The Tickeron PE Growth Rating for this company is 31 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating fairly steady price growth. CVS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 81 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 82 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CVS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 88, placing this stock better than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
an integrated pharmacy health care provider
Industry ManagedHealthCare
Advertisement